Dose–response antiproliferative and proapoptotic properties of Sorafenib, Regorafenib, Lenvatinib, and Cabozantinib in primary human hepatocytes and HCC cell lines according to differentiation and p53 status. Here, TP53 is linked to hepatocellular carcinoma.